ArticleImmunotherapy advances2026
Targeting intratumoral regulatory T cells by CD137 aptamer-shRNA chimeras.
Article in Immunotherapy advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The cytokine CD137 (TNFRSF9, 4-1BB) is best known as a T cell costimulatory molecule. However, CD137 is also part of a negative feedback mechanism that limits T cell activation, and that is employed by regulatory T cells (Tregs) to prevent an overstimulation of T cells and subsequent autoimmune damage. CD137 has been identified as the gene that most significantly distinguishes intra- from extratumoral Tregs. CD137 Methods and Results: We fused the aptamer to short hairpin (sh) RNAs that are specific for Enhancer of zeste homolog 2 (EzH2) or neuropilin-1 (Nrp1), and demonstrated their uptake into CD137 Conclusion: This study confirms CD137 as a target for tumor immunotherapy and introduces CD137 aptamer-shRNA chimeras as novel tools to be evaluated for their usefulness in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.